Presentation is loading. Please wait.

Presentation is loading. Please wait.

Schematic representation of main EGFR-TKIs resistance mechanisms.

Published byHugo Valverde Álvarez Modified over 5 years ago

Similar presentations

Presentation on theme: "Schematic representation of main EGFR-TKIs resistance mechanisms."— Presentation transcript:

1 Schematic representation of main EGFR-TKIs resistance mechanisms.
Schematic representation of main EGFR-TKIs resistance mechanisms. Resistance to EGFR-TKIs can occur through different mechanisms either intrinsic or acquired. Known mechanisms are secondary resistance mutations occurring in the ATP-binding domain (such as T790M and C797S), mutation or amplification of bypass signallings (such as AXL, Hh, ERBb2, CRIPTO, etc), activating mutations in the downstream pathways (PI3K, AKT, MEK, RAF), low levels of mRNA or polymorphisms of the pro-apoptotic protein BIM, induction of a transcription programme for EMT and phenotypical changes, or induction of elevated tumour PD-L1 levels. EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; mRNA, messenger RNA; PD-1, programmed death receptor-1; PD-L1, programmed death ligand-1; TKI, tyrosine kinase inhibitor. Floriana Morgillo et al. ESMO Open 2016;1:e000060 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Schematic representation of main EGFR-TKIs resistance mechanisms."

Similar presentations

In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.

In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.
Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
Epidermal growth factor receptor (EGFR) mutations in NSCLC

Epidermal growth factor receptor (EGFR) mutations in NSCLC
Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.
Samsung Genome Institute Samsung Medical Center

Samsung Genome Institute Samsung Medical Center
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Sustaining Proliferative Signaling and Evading Growth Suppressors

Sustaining Proliferative Signaling and Evading Growth Suppressors
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,
cMET Exon 14 Skipping: From the Structure to the Clinic

cMET Exon 14 Skipping: From the Structure to the Clinic
Figure 2 Three distinct mechanisms of activation of

Figure 2 Three distinct mechanisms of activation of
Figure 1 A schematic representation of the HER2 signalling pathway

Figure 1 A schematic representation of the HER2 signalling pathway
Figure 2 Oestrogen receptor signalling pathways

Figure 2 Oestrogen receptor signalling pathways
Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).
BDNF and insulin signaling pathways activated by phytochemicals.

BDNF and insulin signaling pathways activated by phytochemicals.
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Similar presentations

Ads by Google